The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.31
Bid: 1.30
Ask: 1.33
Change: -0.015 (-1.13%)
Spread: 0.03 (2.308%)
Open: 1.31
High: 1.32
Low: 1.30
Prev. Close: 1.325
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

1 Nov 2023 10:51

Edison Investment Research Limited Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets 01-Nov-2023 / 10:51 GMT/BST The issuer is solely responsible for the content of this announcement.


 

London, UK, 1 November 2023

 

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO’s shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix’s shareholders would receive new RTWBIO shares at an implied c 46% premium to the level before Arix announced a strategic review. Meanwhile, RTWBIO’s management team anticipates that the deal would be single-digit accretive to the company’s NAV per share at completion.

During 2022 and so far in 2023, RTWBIO has made nine new investments and had seven successful IPOs or exits of portfolio companies. The acquisition would bring c $128m of Arix’s liquid assets, of which c $60m is expected to be in cash following completion of the scheme and the cost of the deal. RTWBIO intends to invest this capital in both public and private assets and can deploy cash quickly via investment in its ‘other public’ portfolio, which is made up of listed companies held by other RTW funds, to minimise cash drag. It can also deploy capital through its royalty and structured finance strategy, which provides an income stream with returns that are uncorrelated with equity returns and stock market volatility.Click here to view the full report.All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first company in-market 17 years ago, Edison has more than 100 employees and covers every economic sector. Headquartered in London, Edison also has offices in New York, Sydney and Wellington.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1762757 01-Nov-2023 

corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20244:46 pmRNSAnnual Financial Report
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20249:30 amRNSNotice of AGM
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSMonthly Valuation Update and First Quarter Letter
12th Apr 20245:42 pmRNSPortfolio Company Update: Artios Pharma
12th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 202410:00 amRNSNew Investment: Obsidian Therapeutics
5th Apr 20247:01 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:01 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:01 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSAnnual Financial Report
27th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:01 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSMonthly Valuation Update & Factsheet
11th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSClosed Period Notification
22nd Feb 20243:00 pmRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20243:54 pmRNSHolding(s) in Company
20th Feb 20245:47 pmRNSPost-transaction Manager NAV Estimate
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20244:50 pmRNSHolding(s) in Company
16th Feb 20249:45 amRNSHolding(s) in Company
14th Feb 20247:01 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSMonthly Valuation Update, January Factsheet
13th Feb 20248:11 amRNSCompletion of Acquisition
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:01 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSRTW Biotech Opp. – Investment Update: Kyverna IPO
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSUpdate on Arix Transaction
24th Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSAcacia stake purchase & capital allocation plan
18th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSMonthly Valuation Update, December Factsheet

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.